A Brave New World in a Time of Personalized Therapy

Two Cleveland Clinic experts will co-direct an upcoming ASH Satellite Symposium preceding the 59th ASH Annual Meeting. Join Hetty Carraway, MD, and Sudipto Mukherjee, MD, MPH, both staff in the Department of Hematology and Medical Oncology, for an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

On the afternoon of December 8, faculty from Cleveland Clinic Cancer Center and other top cancer centers around the world will present an exploration of “A Brave New World: The Clinical Management of Bone Marrow Failure and Myeloid Malignancy in a Time of Personalized Therapy.”

“We are honored to be joined by such distinguished faculty from around the world,” says Dr. Carraway. Faculty include:

• Corey Cutler, MD, MPH, Dana Farber Cancer Institute
• Guillermo Garcia-Manero, MD, MD Anderson Cancer Center
• Mark Levis, MD, PhD, Johns Hopkins University School of Medicine
• Laura Michaelis, MD, Medical College of Wisconsin
• Valeria Santini, MD, University of Florence Medical School, Florence, Italy
• Gerard Socie, MD, PhD, St-Louise Hospital, Paris, France

This half-day symposium will enable you to identify the role of targeted therapies in myeloid malignancies, describe the impact of checkpoint inhibitors for the treatment of MDS/AML, describe the genomic mutations in MPNs and their impact on pathogenesis and treatment options and more.

For a full agenda and to register, visit the program site.

This activity has been approved for AMA PRA Category 1 credit™.